PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To study the pharmacokinetics
of 124I-PUH71 in patients with active solid malignancy and/or lymphoma.
2 years
No
Mark Dunphy, DO
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
10-139
NCT01269593
December 2010
December 2013
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |